{"DataElement":{"publicId":"4025055","version":"1","preferredName":"Molecular Neoplasm Profile Therapy Plan Adherence Agreement Integer::5 Point Likert Scale","preferredDefinition":"The 5 point Likert scale response regarding the agreement to molecularly-tailored treatment for patients based on the adherence to the advised treatment plan created as a result of the algorithm.","longName":"MNP_PLADH_AG_5PT_LIK","context":"LCC","contextVersion":"1","DataElementConcept":{"publicId":"4024900","version":"1","preferredName":"Molecular Neoplasm Profile Therapy Plan Adherence","preferredDefinition":"Molecular; relating to or produced by or consisting of molecules._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._An analysis (often in graphical form) representing the extent to which something exhibits various characteristics._Any intervention for management of a malignant neoplasm._To devise, contrive, or form in design._The act of abiding by a stated treatment plan or protocol.","longName":"MNP_THPY_PLAN_ADH","context":"LCC","contextVersion":"1","ObjectClass":{"publicId":"4024879","version":"1","preferredName":"Molecular Neoplasm Profile Therapy","preferredDefinition":"Molecular; relating to or produced by or consisting of molecules.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.:An analysis (often in graphical form) representing the extent to which something exhibits various characteristics.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25574:C3262:C84385:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Molecular","conceptCode":"C25574","definition":"Relating to or produced by or consisting of molecules.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Profile","conceptCode":"C84385","definition":"An analysis (often in graphical form) representing the extent to which something exhibits various characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDEA8D29-127E-6A0E-E040-BB89AD4318C5","latestVersionIndicator":"Yes","beginDate":"2013-12-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-12-19","modifiedBy":"ONEDATA","dateModified":"2013-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4024898","version":"1","preferredName":"Plan Adherence","preferredDefinition":"Planned; devised, contrived, or formed in design.:The act of abiding by a stated treatment plan or protocol.","longName":"C25619:C25729","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plan","conceptCode":"C25619","definition":"To devise, contrive, or form in design.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adherence","conceptCode":"C25729","definition":"The act of abiding by a stated treatment plan or protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDEB241D-8103-B2AE-E040-BB89AD431ACC","latestVersionIndicator":"Yes","beginDate":"2013-12-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-12-19","modifiedBy":"ONEDATA","dateModified":"2013-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2524082","version":"1","preferredName":"Person Measure/Instrument Testing","preferredDefinition":"Process and results associated with self-reported measures and instruments, surveys, other tools","longName":"MEASURE/INSTRUMENT TESTING","context":"CCR","contextVersion":"1","origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E838B40-6636-0A25-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-09-28","modifiedBy":"REEVESD","dateModified":"2008-11-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDEB241D-8114-B2AE-E040-BB89AD431ACC","latestVersionIndicator":"Yes","beginDate":"2013-12-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-12-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Molecular Tumor Profile. LCC. ghd. 12.19.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4011978","version":"1","preferredName":"Agreement Integer::5 Point Likert Scale","preferredDefinition":"an ordered reference standard.","longName":"AGR_5PT_LIK_SCA","context":"LCC","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"5","valueDescription":"Strongly Agree","ValueMeaning":{"publicId":"3682714","version":"1","preferredName":"Strongly Agree","longName":"3682714","preferredDefinition":"Intense concurrence.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Strongly Agree","conceptCode":"C104475","definition":"Intense concurrence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D52DC623-4B36-9139-E040-BB89AD4368ED","latestVersionIndicator":"Yes","beginDate":"2013-02-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-02-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB18D68-7E84-7FA5-E040-BB89AD4330D5","beginDate":"2013-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-12-16","modifiedBy":"ONEDATA","dateModified":"2013-12-16","deletedIndicator":"No"},{"value":"4","valueDescription":"Somewhat Agree","ValueMeaning":{"publicId":"2580090","version":"1","preferredName":"Somewhat Agree","longName":"2580090","preferredDefinition":"Somewhat Agree","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-05E7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-25","endDate":null,"createdBy":"AYANLOWA","dateCreated":"2006-06-25","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB18D68-7E98-7FA5-E040-BB89AD4330D5","beginDate":"2013-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-12-16","modifiedBy":"ONEDATA","dateModified":"2013-12-16","deletedIndicator":"No"},{"value":"3","valueDescription":"Neither Disagree Nor Agree","ValueMeaning":{"publicId":"4011979","version":"1","preferredName":"Neither Disagree Nor Agree","longName":"4011979","preferredDefinition":"Neither Disagree Nor Agree","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDB18D68-7EA3-7FA5-E040-BB89AD4330D5","latestVersionIndicator":"Yes","beginDate":"2013-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB18D68-7EBC-7FA5-E040-BB89AD4330D5","beginDate":"2013-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-12-16","modifiedBy":"ONEDATA","dateModified":"2013-12-16","deletedIndicator":"No"},{"value":"2","valueDescription":"somewhat disagree","ValueMeaning":{"publicId":"2580091","version":"1","preferredName":"somewhat disagree","longName":"2580091","preferredDefinition":"somewhat disagree","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-05E8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-25","endDate":null,"createdBy":"AYANLOWA","dateCreated":"2006-06-25","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB18D68-7ED2-7FA5-E040-BB89AD4330D5","beginDate":"2013-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-12-16","modifiedBy":"ONEDATA","dateModified":"2013-12-16","deletedIndicator":"No"},{"value":"1","valueDescription":"Strongly Disagree","ValueMeaning":{"publicId":"3682710","version":"1","preferredName":"Strongly Disagree","longName":"3682710","preferredDefinition":"Intensely at odds.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Strongly Disagree","conceptCode":"C104476","definition":"Intensely at odds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D52DC623-4AA8-9139-E040-BB89AD4368ED","latestVersionIndicator":"Yes","beginDate":"2013-02-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-02-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB18D68-7EE7-7FA5-E040-BB89AD4330D5","beginDate":"2013-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-12-16","modifiedBy":"ONEDATA","dateModified":"2013-12-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2524082","version":"1","preferredName":"Person Measure/Instrument Testing","preferredDefinition":"Process and results associated with self-reported measures and instruments, surveys, other tools","longName":"MEASURE/INSTRUMENT TESTING","context":"CCR","contextVersion":"1","origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E838B40-6636-0A25-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-09-28","modifiedBy":"REEVESD","dateModified":"2008-11-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2452834","version":"1","preferredName":"Scale","preferredDefinition":"an ordered reference standard.","longName":"C25664","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Scale","conceptCode":"C25664","definition":"An ordered reference standard used to measure incremental changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"0D51E8D8-69DD-387C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDB18D68-7E66-7FA5-E040-BB89AD4330D5","latestVersionIndicator":"Yes","beginDate":"2013-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-12-16","modifiedBy":"HARTLEYG","dateModified":"2013-12-20","changeDescription":"LCC_MolTailorTreat_ghd_12.16.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"I adhered to the advised trea","type":"Preferred Question Text","description":"I adhered to the advised treatment plan based on the algorithm","url":null,"context":"LCC"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDEC2904-8484-C514-E040-BB89AD4374D1","latestVersionIndicator":"Yes","beginDate":"2013-12-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-12-19","modifiedBy":"HARTLEYG","dateModified":"2013-12-20","changeDescription":"Molecular Based Treatment_LCC_ghd_12.19.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}